Craig-Hallum analyst Kevin Ellich raised his price target for Henry Schein to $96 from $83 as Q2 EPS beat Street estimates while revenues were slightly better driven by 4.7% dental consumable growth in North America, the best since Q4 2015. The analyst reiterates a Buy rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.